| 182, 177,99 1.66 | 8,649,586.77 | 3,566,027.15 | 11,671 ,827.83 | 36,520,008.56 | 213,840,036.80 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 5,779.82 | | | | | | | | | | | | | | | | | | | | | | | 118,017,355.78 | 574,775,157.40 | 142,363,100.00 | | | | | | | | | | | | | | | | | | | | | 326,543.03 | 1,035,871.46 | | | | | | | | | | | | | | | | | | | | | | 65,990,600.62 | 467,254,877 ...

福建广生堂药业股份有限公司 关于公司申请向特定对象发行股票的审核问询函回复（修订 稿）及募集说明书等申请文件更新的提示性公告 证券代码：300436 证券简称：广生堂 公告编号：2026002 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日收 到深圳证券交易所（以下简称"深交所"）出具的《关于福建广生堂药业股份有 限公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号） （以下简称"问询函"），深交所发行上市审核机构对公司向特定对象发行股票 的申请文件进行了审核，并形成了审核问询问题。 根据深交所进一步的审核意见，公司会同中介机构对问询函回复的部分内容、 募集说明书等申请文件进行了相应补充、更新和修订。鉴于公司 2025 年第三季 度报告已公开披露，公司会同中介机构对募集说明书等申请文件中涉及的财务数 据等内容进行了同步更新。具体内容详见公司于 2026 年 1 月 13 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告文件。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称" ...

关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函有 关财务事项的说明 德皓函字[2026]00000005 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 目 录 页 次 一、 关于福建广生堂药业股份有限公司申请向特定 对象发行股票的审核问询函有关财务事项的说 明 1-152 关 于 福 建 广 生 堂 药 业 股 份 有 限 公 司 申 请 向 特 定 对 象 发 行 股 票 的 审 核 问 询 函 有 关 财 务 事 项 的 说 明 德皓函字[2026]00000005号 深圳证券交易所： 由福建广生堂药业股份有限公司转来的深圳证券交易所《关于福建广生堂药业股份有限 公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号，以下简称问询 函）奉悉。我们已对问询函中由会计师核 ...

广生堂公告称，2025年6月13日收到深交所关于向特定对象发行股票的审核问询函。根据审核意见，公 司会同中介机构对问询函回复部分内容、募集说明书等申请文件补充、更新和修订，同步更新涉及的财 务数据。本次发行尚需通过深交所审核并获中国证监会同意注册，最终结果及时间不确定，公司将及时 披露进展。 ...

Core Viewpoint - Guangshentang's stock price has shown fluctuations, with a recent increase of 2.04% on January 9, 2025, while facing significant challenges in revenue and profit margins [1][2]. Group 1: Stock Performance - As of January 9, 2025, Guangshentang's stock price reached 92.93 CNY per share, with a trading volume of 4.25 billion CNY and a turnover rate of 3.44%, resulting in a total market capitalization of 14.801 billion CNY [1]. - Year-to-date, Guangshentang's stock has increased by 4.24%, with a 4.24% rise over the last five trading days, a 1.40% increase over the last 20 days, and a decline of 22.56% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, while the net profit attributable to shareholders was -112 million CNY, a significant decline of 57.96% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 84.6485 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, Guangshentang had 45,800 shareholders, an increase of 125.95% from the previous period, with an average of 2,985 circulating shares per shareholder, down by 55.74% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, while the China Europe Medical Health Mixed A fund has reduced its holdings by 1.1365 million shares, now holding 708,100 shares [3].

（文章来源：每日经济新闻） 有投资者在投资者互动平台提问：您好董秘，请问公司141产品三期临床进展怎么样了？ 有投资者在投资者互动平台提问：您好董秘，请问公司141产品三期临床进展怎么样了？ 广生堂（300436.SZ）1月8日在投资者互动平台表示，我司GST-HG141的III期临床试验正在顺利推进， 目前入组人数已过半，整体进展符合预期，且日前GST-HG141相关研究已被纳入新发突发与重大传染 病防控国家科技重大专项，有望依托国家重大专项的资源与政策支持，加快研发进展，力争早日获批上 市，惠及广大患者。后续进展公司将依法依规及时披露，敬请持续关注。 广生堂（300436.SZ）1月8日在投资者互动平台表示，我司GST-HG141的III期临床试验正在顺利推进， 目前入组人数已过半，整体进展符合预期，且日前GST-HG141相关研究已被纳入新发突发与重大传染 病防控国家科技重大专项，有望依托国家重大专项的资源与政策支持，加快研发进展，力争早日获批上 市，惠及广大患者。后续进展公司将依法依规及时披露，敬请持续关注。 （文章来源：每日经济新闻） ...

广生堂（300436.SZ）1月8日在投资者互动平台表示，我司GST-HG141的III期临床试验正在顺利推进， 目前入组人数已过半，整体进展符合预期，且日前GST-HG141相关研究已被纳入新发突发与重大传染 病防控国家科技重大专项，有望依托国家重大专项的资源与政策支持，加快研发进展，力争早日获批上 市，惠及广大患者。后续进展公司将依法依规及时披露，敬请持续关注。 每经AI快讯，有投资者在投资者互动平台提问：您好董秘，请问公司141产品三期临床进展怎么样了？ （记者 张明双） ...

Group 1 - The company, Fujian Guangshengtang Pharmaceutical Co., Ltd., is participating in a national major science and technology project aimed at exploring new treatment options for chronic hepatitis B, which has received official approval from the National Health Commission [2][3]. - The project, titled "Research on New Combined Treatment Plans for Clinical Cure of Chronic Hepatitis B," is led by Southern Medical University and will run from December 2025 to November 2028, focusing on improving clinical cure rates and developing guidelines for hepatitis B treatment in China [3][4]. - The company is involved in two specific research topics within the project, which include studies on the use of antisense oligonucleotides and multi-target sequential therapies to enhance clinical cure rates for hepatitis B [4]. Group 2 - The project is significant as it aligns with national health strategies, including the "Healthy China 2030" plan, and aims to strengthen the country's capacity to respond to emerging infectious diseases [4][5]. - Data from Polaris Observatory indicates that there are approximately 79.74 million HBV carriers in China, with chronic hepatitis B patients numbering between 20 million and 30 million, highlighting the public health challenge posed by this disease [5]. - The national action plan for hepatitis B prevention and treatment aims for an 80% diagnosis rate and an 80% treatment rate for chronic hepatitis B patients by 2030, marking a shift towards a focus on "cure" [6]. Group 3 - As a participant in the national project, the company will collaborate closely with leading research teams and clinical centers, which may enhance its competitive edge in the hepatitis B treatment sector [7]. - The company's innovative drugs, GST-HG141 and GST-HG131, have been recognized as breakthrough treatment candidates and are currently undergoing clinical trials, with GST-HG141 having successfully enrolled its first participant in a Phase III trial [7]. - The sequential combination therapy plan, part of the company's "Hepatitis B Summit Plan," is positioned as an exploratory research scheme within the national project, which could facilitate the clinical development and commercialization of its innovative drugs [7].

智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司(简 称"广生中霖")参与申报的新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合治 疗新方案研究"项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广生中霖 作为课题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的研究工作，且在研乙肝创新药 GST-HG131、GST-HG141及联合用药将作为项目课题研究用药。 ...

广生堂（300436）(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司(简称"广生 中霖")参与申报的新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临床治愈联合治疗新方 案研究"项目已获得国家卫生健康委医药卫生科技发展研究中心下发的立项完成通知。广生中霖作为课 题参与单位参与该乙肝治愈专项项目课题一、课题三，负责课题的研究工作，且在研乙肝创新药GST- HG131、GST-HG141及联合用药将作为项目课题研究用药。 ...